# Tevogen Inc.: overview TVGN · Nasdaq · CIK 1860871 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tvgn.md) · [Financials](/companies/tvgn/financials.md) · [Filings](/companies/tvgn/filings.md) · [Insiders](/companies/tvgn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(3.25)](/filings/0001493152-26-023920.md) | [(1.71)](/filings/0001493152-26-038509.md) | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(1.61)](/filings/0001493152-26-023920.md) | [(1.52)](/filings/0001493152-26-038509.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(2.44)](/filings/0001641172-25-002426.md) | [(3.50)](/filings/0001493152-26-014326.md) | [(8.08)](/filings/0001493152-26-014326.md) | | Free cash flow | $m | not reported | [(8.3)](/filings/0001641172-25-002426.md) | not reported | [(12.4)](/filings/0001493152-26-014326.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tvgn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FourWorld Capital Management LLC](/funds/1770525.md) | 2026-06-30 | $8.2m | 1,450,000 | | Unchanged | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $141.5k | 25,000 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $135.7k | 23,976 | | Reduced −9,272 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $106.5k | 18,809 | | Added +1,475 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $97.6k | 17,237 | | New +17,237 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $80.2k | 14,163 | | New +14,163 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $63.3k | 11,175 | | New +11,175 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $58.5k | 1,027,391 | | Added +637,174 | | [Calamos Advisors LLC](/funds/1316507.md) | 2026-06-30 | $56.9k | 1,000,000 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $55.6k | 9,826 | | Reduced −331 | ## Recent filings [All 305 filings](/companies/tvgn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 16:40 ET | [8-K](/filings/0001493152-26-045123.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-045123 | | 2026-09-16 | 20:07 ET | [SCHEDULE 13D/A](/filings/0001123292-26-001317.md) | Ownership report, active investor, amended | 0001123292-26-001317 | | 2026-09-16 | 20:04 ET | [SCHEDULE 13D/A](/filings/0001123292-26-001316.md) | Ownership report, active investor, amended | 0001123292-26-001316 | | 2026-09-16 | 17:12 ET | [8-K](/filings/0001493152-26-042952.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-042952 | | 2026-09-10 | 09:19 ET | [8-K](/filings/0001493152-26-042095.md) | 8.01 Other events | 0001493152-26-042095 | | 2026-08-26 | 15:10 ET | [8-K](/filings/0001493152-26-040216.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-040216 | | 2026-08-14 | 17:16 ET | [10-Q](/filings/0001493152-26-038509.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038509 | | 2026-08-03 | 09:20 ET | [DEF 14A](/filings/0001493152-26-035757.md) | Proxy statement, period 2026-08-03 | 0001493152-26-035757 | | 2026-07-30 | 08:31 ET | [8-K](/filings/0001493152-26-035334.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-035334 | | 2026-07-14 | 21:56 ET | [SCHEDULE 13D/A](/filings/0001123292-26-001010.md) | Ownership report, active investor, amended | 0001123292-26-001010 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014326.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1860871 - Tickers: TVGN, TVGNW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.